Physician profile
Andrew Nava
NPI 1639285323
$13,780.86
in general payments reported to CMS, 2019-2025
44 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $1,737 · 2021: $2,108 · 2022: $1,690 · 2023: $2,786 · 2024: $2,560 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,444 · Education: $83.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,443.83 |
| Education | $83.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,773.80 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $1,071.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,070.22 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $992.89 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $847.60 | 2020-2025 | |
| Eisai INC. | $824.16 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $801.16 | 2021-2025 | |
| Novo Nordisk INC | $704.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $617.25 | 2019-2024 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.04 | 2019-2024 | Xifaxan |
| Amgen INC. | $380.55 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $310.66 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $303.12 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $235.28 | 2019-2022 | |
| Pfizer INC. | $228.94 | 2019-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $226.60 | 2019-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $184.65 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $172.94 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $152.84 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $144.46 | 2024 | Voquezna |
| Astellas Pharma US INC | $138.60 | 2020-2025 | Veozah |
| Merck Sharp & Dohme LLC | $138.36 | 2019-2025 | Capvaxive, Gardasil 9 |
| Allergan, INC. | $133.90 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $116.51 | 2021-2024 | Contrave, Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $110.75 | 2020-2023 | Trintellix |
| Xeris Pharmaceuticals, INC. | $101.01 | 2021-2024 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $82.30 | 2020-2021 | |
| Sanofi Pasteur INC. | $73.98 | 2019-2022 | |
| Gilead Sciences, INC. | $56.66 | 2019-2021 | |
| Exact Sciences Corporation | $54.17 | 2024-2025 | Cologuard Collection Kit |
| Organon LLC | $39.88 | 2023 | Nexplanon |
| Genentech USA, INC. | $37.74 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $33.17 | 2019 | |
| Lundbeck LLC | $30.73 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $30.69 | 2022-2023 | Quviviq |
| Hologic Sales and Service, LLC | $23.90 | 2023 | Aptima |
| Boston Scientific Corporation | $23.44 | 2025 | Ams 700 |
| Strongbridge US INC. | $22.58 | 2019 | |
| Axsome Therapeutics, INC. | $19.45 | 2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $18.89 | 2020 | |
| Esperion Therapeutics, INC. | $18.42 | 2020 | |
| Corium, LLC | $17.29 | 2023 | Adlarity |
| Teleflex LLC | $14.72 | 2021 | |
| Philips North America LLC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Nava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.